Holen Sie sich die Stockscreener-App
31.84
4.47%
1.375
Schlusskurs vom Vortag:
$30.47
Offen:
$30.88
24-Stunden-Volumen:
83,267
Relative Volume:
0.22
Marktkapitalisierung:
$965.71M
Einnahmen:
$339.92M
Nettoeinkommen (Verlust:
$-12.83M
KGV:
-74.14
EPS:
-0.4295
Netto-Cashflow:
$4.52M
1W Leistung:
+13.32%
1M Leistung:
+33.58%
6M Leistung:
-2.80%
1J Leistung:
+61.99%
1-Tages-Spanne:
$30.65
$31.96
1-Wochen-Bereich:
$27.83
$31.96
52-Wochen-Spanne:
$17.72
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Firmenname
Castle Biosciences Inc
Sektor
Branche
Telefon
866-788-9007
Adresse
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
31.84 | 741.26M | 339.92M | -12.83M | 4.52M | -0.4295 |
TMO
Thermo Fisher Scientific Inc
|
587.66 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
204.08 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
589.39 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
321.32 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
144.82 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-04-30 | Eingeleitet | Lake Street | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | BTIG Research | Buy |
| 2019-08-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Castle Biosciences Inc (CSTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Castle Biosciences Inc (CSTL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Castle Biosciences Inc (CSTL) Cash Flow - TradingKey
Earnings Preview: CSTL to Report Financial Results Post-market on July 30 - Moomoo
Castle Biosciences Inc (CSTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Castle Biosciences, Inc. (CSTL) Investor Outlook: Exploring A 67.89% Potential Upside - DirectorsTalk Interviews
CSTL|Castle Biosciences Inc|Price:25.093|Chg%:-0.387 - TradingKey
Castle Biosciences sets live webcast for Aug. 12 conference - Stock Titan
New York State Department of Health Approves Castle’s AdvanceAD-Tx Test - The Dermatology Digest
The Technical Signals Behind (CSTL) That Institutions Follow - Stock Traders Daily
Castle Biosciences CEO Maetzold sells $95,622 in company stock - Investing.com UK
Form 4 Castle Biosciences Inc For: 16 July By Investing.com - Investing.com Nigeria
Castle Biosciences CEO Maetzold sells $95,622 in company stock By Investing.com - Investing.com UK
Castle Biosciences (CSTL) CEO sells 4,172 shares via family trusts - Stock Titan
Castle Biosciences CEO Derek J. Maetzold disposes of 550 common shares worth $12,606 - Bitget
Castle Biosciences Gets New York State Department of Health Approval of AdvanceAD-Tx Test - Moomoo
Castle Biosciences receives New York approval for atopic dermatitis test By Investing.com - Investing.com Nigeria
Castle Biosciences receives New York approval for atopic dermatitis test - Investing.com
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test - norfolkneradio.com
CSTL Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Uncertain Revenue Outlook - DonanımHaber
Castle Biosciences Inc (CSTL) Stock Down 3.4% -- Now Undervalued? GF Score: 77/100 - GuruFocus
CSTL Q1 2026 Earnings: Slight EPS Beat Amid Operational ProgressRevenue Guidance Update - DonanımHaber
July 30 set for Castle Biosciences Q2 2026 earnings webcast - Traders Union
Castle Biosciences (CSTL) to Release Q2 Financial Results on Jul - GuruFocus
Castle Biosciences sets July 30 webcast for Q2 results - Stock Titan
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 - Yahoo Finance
Castle Biosciences updates its melanoma testing strategy as diagnostics demand grows - Ad-hoc-news.de
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus - AOL.com
Castle Biosciences (CSTL) COO sells 8,586 shares under 10b5-1 plan - Stock Titan
Form 4 Castle Biosciences Inc For: 6 July By Investing.com - Investing.com Nigeria
Derek Maetzold, pres. & CEO, sells $238,916 of Castle Biosciences stock - Investing.com India
Castle Biosciences (CSTL) CEO sells 9,836 shares via 10b5-1 plan - Stock Titan
Q1 2026 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Enterprise value to revenue forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Castle Biosciences Inc (CSTL) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 144 Castle Biosciences For: 1 July By Investing.com - Investing.com Canada
Maetzold family Rule 144 sales reported for CSTL (CSTL) — multiple small lots - Stock Titan
Castle Biosciences (CSTL) Surges 6% as Bullish Momentum BuildsDynamic Hedging - dars.gov.et
Castle Biosciences updates its melanoma test data, shares in biotech focus - AD HOC NEWS
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down - Yahoo Finance
Castle Biosciences (CSTL) Study Highlights Advancements in Melan - GuruFocus
Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool By Investing.com - Investing.com South Africa
Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool - Investing.com
Enterprise value to EBIT forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy - norfolkneradio.com
Roth Capital Initiates Castle Biosciences at Buy - Moomoo
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones - Stock Traders Daily
Finanzdaten der Castle Biosciences Inc-Aktie (CSTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Castle Biosciences Inc-Aktie (CSTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Juvenal Tobin W | Chief Commercial Officer |
Jul 31 '26 |
Sale |
29.31 |
17,310 |
507,302 |
80,725 |
| Juvenal Tobin W | Chief Commercial Officer |
Aug 03 '26 |
Sale |
28.25 |
1,730 |
48,872 |
78,995 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Aug 03 '26 |
Option Exercise |
2.39 |
10,664 |
25,487 |
32,143 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 31 '26 |
Option Exercise |
2.39 |
6,480 |
15,487 |
27,959 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Aug 03 '26 |
Sale |
30.35 |
10,664 |
323,684 |
21,479 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Aug 03 '26 |
Sale |
30.35 |
7,829 |
237,634 |
27,009 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 31 '26 |
Sale |
30.15 |
6,480 |
195,385 |
21,479 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 31 '26 |
Sale |
30.15 |
3,673 |
110,748 |
30,606 |
0.06%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):